Intra-Cellular Therapies, Inc.
ITCIHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $144.9M | $95.3M | $250.3M | $83.8M | $22.8M | $60,613 |
| Operating income | −$116.7M | −$159.4M | −$263.6M | −$285.7M | −$231.2M | −$154.0M |
| Net income | −$15.2M | −$44.1M | −$256.3M | −$284.1M | −$227.0M | −$147.7M |
| Total assets | $1.37B | $728.3M | $754.8M | $489.9M | $717.3M | $251.2M |
| Total liabilities | $218.5M | $136.9M | $98.7M | $72.0M | $60.5M | $56.2M |
| Equity | $1.15B | $591.4M | $656.1M | $417.9M | $656.9M | $195.0M |
| EPS (diluted) | $-0.16 | $-0.46 | $-2.72 | $-3.50 | $-3.23 | — |
| Shares out. | 96.8M | 95.3M | 93.6M | 80.9M | 66.1M | 55.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −80.6%
- Net margin
- −10.5%
- Return on equity
- −1.3%
- Return on assets
- −1.1%
- Return on capital (ROCE)
- −10.1%
- Liabilities / assets
- 16.0%
- Debt / equity
- 0.19×
- Book value / share
- $11.86
- Revenue growth (YoY)
- 52.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 6.20safe
- Accruals / assets
- 4.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jul 2, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-03Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania
- Phase 3Recruitingreadout ~2026-05Study of Lumateperone in the Treatment of Patients With Bipolar Mania
- Phase 1Recruitingreadout ~2026-07PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
- Phase 1Recruitingreadout ~2026-07-31Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder
- Phase 3Recruitingreadout ~2026-09Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Phase 3Recruitingreadout ~2027-03Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
- Phase 3Recruitingreadout ~2027-03Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
- Phase 3Recruitingreadout ~2027-04Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Jpmorgan Chase & CoPassive (13G)Jun 5, 2025
- Fmr LlcPassive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Mar 31, 2025 | 2.6M | 1.8 | -3.1% |
| Mar 14, 2025 | 2.7M | 1.0 | +14.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 2, 2025
- Shareholder voteMar 27, 2025
- Other material eventMar 18, 2025
- Other material eventMar 3, 2025
- Results of operations · Other material eventFeb 21, 2025
- Entered a material agreement · Regulation FD disclosureJan 13, 2025
- Other material eventJan 10, 2025
- Other material eventDec 3, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.